Related Experiment Video

Updated: Nov 4, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

23.7K

Botulinum Toxin Type A injections for pediatric spasticity: Keeping our patients informed and practices safe

Edward Wright1,2, Lauren Fetsko1

  • 1Baylor College of Medicine, Houston, TX, USA.

Journal of Pediatric Rehabilitation Medicine
|May 31, 2021
PubMed

Insights

Serious adverse events from Botulinum Toxin Type A (BoNT-A) are rare in pediatric spasticity. Clear communication and informed consent are vital for managing risks and potential litigation.

Area of Science:

  • Neurology
  • Pediatrics
  • Medical Law

Background:

  • Serious adverse events (AEs) following Botulinum Toxin Type A (BoNT-A) therapy are uncommon.
  • Pediatric spasticity patients often have comorbidities complicating AE attribution.
  • Litigation risk is a concern following BoNT-A treatment in children.

Purpose of the Study:

  • To analyze litigation related to BoNT-A for pediatric spasticity.
  • To identify potential discrepancies between provider and public perspectives on BoNT-A risks.
  • To provide recommendations for optimizing informed consent content.

Main Methods:

  • Review of legal cases involving BoNT-A in pediatric spasticity.
  • Analysis of documentation practices, informed consent, and provider-patient relationships.
  • Examination of factors contributing to litigation.

Main Results:

  • Litigation highlights differing perspectives on BoNT-A risks and benefits.
  • Inadequate informed consent and documentation increase litigation vulnerability.
  • Comorbidities in pediatric patients can complicate AE causality assessments.

Conclusions:

  • Enhanced informed consent processes are crucial for managing patient expectations and reducing litigation.
  • Clear documentation of information sharing and the provider-patient relationship is essential.
  • Understanding potential legal ramifications is important for healthcare providers administering BoNT-A.

Keywords:
Black Box WarningBotulinum Toxin Type ACerebral PalsyFDA labelcausationconsentidiosyncratic reactionsindicationinformation sharingmedication guideoff label drug usepediatric spasticityserious adverse events

More Related Videos

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.2K
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.5K

Related Concept Videos

Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
710
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
873
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
561
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.8K
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.1K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
425